AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.06 -1.88%

-$1.07 today

Market cap
$1.40B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.57M

Average 0.76M

ANAB Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

AnaptysBio, Inc.NASDAQ: ANAB

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $26.2M rose 85.4% year over year, ahead of the +42.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 66.0% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.

Context

  • Selling, general & admin amounted to 21.6% of revenue in FY2025, down 24.8 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $213.28M (+320.4%) for the fiscal year ending Dec 2026, a step up from the +19.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.2M+66.0% QoQ
Last fiscal yearDec 2025
$50.74M+19.7% YoY
LTMMar 2026
$62.81M+42.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+85.4%+195.0%+109.5 pp
1 year+19.7%+320.4%+300.7 pp
3-year CAGR+11.5%+103.6%+92.1 pp
5-year CAGR+62.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
50.74M USD
Year-over-year change
+19.7%
4-year CAGR
+24.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ANAB compares with its peers on the latest reported figures

  • ANAB's LTM Mar 2026 selling, general & admin of $62.81M is the 3rd highest of the 10 companies compared; the peer median is $32.75M.
  • Its year-over-year change of +42.2% is the 2nd highest of 10, against a peer median of +5.5%.
  • Selling, general & admin amounts to 27.0% of revenue for ANAB, versus a peer median of 625.0%.
ANAB Competitors Peer median
Selling, General & Admin for ANAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$69.54M -16.7%+16.7%980.1%
XNCRXencor, Inc.LTM Jun 2026$65.29M +5.1%+10.3%62.2%
ANABAnaptysBio, Inc.LTM Mar 2026$62.81M +42.2%+11.5%27.0%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$46.46M +34.5%+22.2%—
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$44.15M +49.3%+72.0%2318.8%
ANNXAnnexon, Inc.LTM Mar 2026$32.75M -0.8%+0.8%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$22.58M +5.5%-4.4%269.8%
CNTBConnect Biopharma Holdings LimitedFY2025$20.34M +5.8%-0.8%31781.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$20.27M +8.2%-0.8%—
QTTBQ32 Bio Inc.LTM Mar 2026$17.08M -4.8%+20.7%31.8%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ANAB) $32.75M+5.5%+10.3%625.0%

Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.18M10.29M17.16M91.28M234.6M
Cost of Revenue98.5M88.8M132.28M163.84M2.42M
Gross Profit(35.32M)(78.51M)(115.13M)(72.56M)232.18M
Gross Margin-55.9%-763.2%-671.0%-79.5%99.0%
Research & Development98.5M88.8M139.62M163.84M135.97M
Selling, General & Admin21.49M36.64M41.95M42.39M50.74M
Operating Expenses21.49M36.64M49.29M42.39M184.28M
Depreciation & Amortization2.09M2.34M652K2.4M2.42M
EBITDA(55.71M)(105.26M)(156.42M)(92.74M)69.25M
EBITDA Margin-88.2%-1023.2%-911.7%-101.6%29.5%
Operating Income(56.81M)(115.15M)(164.41M)(114.95M)47.9M
Operating Margin-89.9%-1119.4%-958.3%-125.9%20.4%
Interest Income431K7.55M18.87M19.79M13.5M
Interest Expense1.45M21.11M18.08M50.09M79.89M
Other Income / Expenses(982K)(13.55M)788K(30.28M)(60.96M)
Income Before Tax(57.8M)(128.7M)(163.62M)(145.23M)(13.07M)
Pre-Tax Margin-91.5%-1251.1%-953.7%-159.1%-5.6%
Income Tax Expense024K(4K)3K164K
Net Income(57.8M)(128.72M)(163.62M)(145.23M)(13.23M)
Net Margin-91.5%-1251.3%-953.7%-159.1%-5.6%
EPS (Basic)(2.11)(4.57)(6.08)(5.12)(0.46)
EPS (Diluted)(2.11)(4.57)(6.08)(5.12)(0.46)
Weighted Avg Shares27.43M28.17M26.92M28.38M27.79M
Weighted Avg Shares (Diluted)27.43M28.17M26.92M28.38M31.34M

AnaptysBio, Inc.

NASDAQ:ANAB

Intrinsic Alpha fair value

Locked

Current Price

$47.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.